A first aspect of the present invention is a method of treating a proliferative disorder in a subject, a therapeutically effective amount of: (i) Sapashitabin or its metabolites and (ii) seliciclib, at least once a first treatment period of and comprising administering to a subject in accordance with the dosing regimen comprising at least one second treatment period of the first treatment period, (a) a therapeutically effective amount of a Sapashitabin or continuous 3 to the metabolite 2 weeks 5 days the method comprising administering, in the first treatment cycle, it is administered beginning on Sapashitabin or d-th day treatment is of the first day of its metabolites and (b) optionally, the method comprising administering consecutive 3-5 days seliciclib therapeutically effective amount for two weeks, in the first treatment cycle, Sapashitabin or starting the (d-1) Sun th against the administration of its metabolites It is administered includes a rest period is any longer until at least two weeks or treatment-related toxicity following it is eliminated, the second treatment period, (a) a therapeutically effective amount of Sapashitabin or its metabolite the the method comprising administering consecutive 3-5 days for two weeks, in the second treatment cycle, be administered starting on d-th day treatment is of the first day in Sapashitabin or its metabolites and (b) a by administering consecutive 3-5 days seliciclib therapeutically effective amount for two weeks, in the second treatment cycle, the Sapashitabin or (d-1) -th day for the administration of the metabolite It is administered starting the method comprising the rest periods is either longer until at least two weeks, or treatment-related toxicities followed is eliminated. A further aspect of the invention relates to a kit-of-parts and corresponding uses.本発明の第1の態様は、対象における増殖性障害を治療する方法であって、治療有効量の(i)サパシタビン又はその代謝産物及び(ii)セリシクリブを、少なくとも1回の第1の治療周期及び少なくとも1回の第2の治療周期を含む投薬レジメンに従って対象に投与することを含み、前記第1の治療周期が、(a)治療有効量のサパシタビン
